nach oben

Erschienen in:

01.05.2015 | Main topic

Sports in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy and desmosomal mutations

verfasst von: A.C. Sawant, H. Calkins, MD

Erschienen in: Herz | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a rare cardiomyopathy associated with life-threatening arrhythmias and an increased risk of sudden cardiac death. In addition to mutations in desmosomal genes, environmental factors such as exercise and sport have been implicated in the pathogenesis of the disease. Recent studies have shown that exercise may be associated with adverse outcomes in patients with ARVD/C. On the basis of current evidence, patients with ARVD/C are recommended to limit exercise irrespective of their mutation status. Some studies have suggested the presence of an entirely acquired form of the disease caused by exercise, which has been dubbed “exercise-induced ARVD/C.”

Marcus FI, Fontaine GH, Guiraudon G et al (1982) Right ventricular dysplasia: a report of 24 adult cases. Circulation 65:384–398CrossRefPubMed

Basso C, Corrado D, Marcus FI et al (2009) Arrhythmogenic right ventricular cardiomyopathy. Lancet 373:1289–1300CrossRefPubMed

Thiene G, Nava A, Corrado D et al (1988) Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 318:129–133CrossRefPubMed

Dalal D, Nasir K, Bomma C et al (2005) Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation 112:3823–3832CrossRefPubMed

Saguner AM, Brunckhorst C, Duru F (2014) Arrhythmogenic ventricular cardiomyopathy: a paradigm shift from right to biventricular disease. World J Cardiol 6:154–174CrossRefPubMedCentralPubMed

Gerull B, Heuser A, Wichter T et al (2004) Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet 36:1162–1164CrossRefPubMed

Rampazzo A, Nava A, Malacrida S et al (2002) Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 71:1200–1206CrossRefPubMedCentralPubMed

Syrris P, Ward D, Evans A et al (2006) Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet 79:978–984CrossRefPubMedCentralPubMed

Haan AD den, Tan BY, Zikusoka MN et al (2009) Comprehensive desmosome mutation analysis in North Americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet 109:428–435CrossRef

10.

Cox MG, Zwaag PA van der, Werf C van der et al (2011) Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/cardiomyopathy genotype-phenotype follow-up study. Circulation 123:2690–2700CrossRefPubMed

11.

Pilichou K, Nava A, Basso C et al (2006) Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation 113:1171–1179CrossRefPubMed

12.

Awad MM, Dalal D, Cho E et al (2006) DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Hum Genet 79:136–142CrossRefPubMedCentralPubMed

13.

Quarta G, Syrris P, Ashworth M et al (2012) Mutations in the Lamin A/C gene mimic arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 33:1128–1136CrossRefPubMed

14.

Zwaag PA van der, Rijsingen IAW van, Asimaki A et al (2012) Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail 14:1199–1207CrossRefPubMedCentralPubMed

15.

Calore M, Lorenzon A, De Bortoli M et al (2014) Arrhythmogenic cardiomyopathy: a disease of intercalated discs. Cell Tissue Res (Epub ahead of print)

16.

Hengel J van, Calore M, Bauce B et al (2013) Mutations in the area composita protein alphaT-catenin are associated with arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 34:201–210CrossRefPubMed

17.

Peters S, Trummel M, Meyners W (2004) Prevalence of right ventricular dysplasia-cardiomyopathy in a non-referral hospital. Int J Cardiol 97:499–501CrossRefPubMed

18.

Nava A, Thiene G, Canciani B et al (1998) Familial occurrence of right ventricular dysplasia: a study involving nine families. J Am Coll Cardiol 12:1222–1228CrossRef

19.

Basso C, Corrado D, Thiene G (1999) Cardiovascular causes of sudden death in young individuals including athletes. Cardiol Rev 7:127–135CrossRefPubMed

20.

Marcus FI, Zareba W, Calkins H et al (2009) Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm 6:984–992CrossRefPubMedCentralPubMed

21.

Quarta G, Muir A, Pantazis A et al (2011) Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation 123:2701–2709CrossRefPubMed

22.

Riele AS te, James CA, Rastegar N et al (2014) Yield of serial evaluation in at-risk family members of patients with ARVD/C. J Am Coll Cardiol 64:293–301CrossRef

23.

Riele AS te, Bhonsale A, James CA et al (2013) Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol 62:1761–1769CrossRef

24.

Riele AS te, Tandri H, Bluemke DA (2014) Arrhythmogenic right ventricular cardiomyopathy (ARVC): cardiovascular magnetic resonance update. J Cardiovasc Magn Reson 16:50CrossRef

25.

Philips B, Madhavan S, James CA et al (2014) Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol 7:230–236CrossRefPubMed

26.

Groeneweg JA, Bhonsale A, James CA et al (2014) Abstract 13189: clinical presentation, long-term follow-up, and disease penetrance of arrhythmogenic right ventricular dysplasia/cardiomyopathy in 1001 patients and family members. Circulation 130:A13189

27.

McKoy G, Protonotarios N, Crosby A et al (2000) Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 355:2119–2124CrossRefPubMed

28.

Protonotarios N, Tsatsopoulou A (2004) Naxos disease and carvajal syndrome: cardiocutaneous disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Pathol 13:185–194CrossRefPubMed

29.

Bhonsale A, Groeneweg JA, James CA et al (2014) Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy associated mutation carriers. Eur Heart J (Epub ahead of print)

30.

Tandri H, Asimaki A, Dalal D et al (2008) Gap junction remodeling in a case of arrhythmogenic right ventricular dysplasia due to plakophilin-2 mutation. J Cardiovasc Electrophysiol 19:1212–1214CrossRefPubMed

31.

Oxford EM, Musa H, Maass K et al (2007) Connexin43 remodeling caused by inhibition of plakophilin-2 expression in cardiac cells. Circ Res 101:703–711CrossRefPubMed

32.

Merner ND, Hodgkinson KA, Haywood AF et al (2008) Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet 82:809–821CrossRefPubMedCentralPubMed

33.

Beffagna G, Occhi G, Nava A et al (2005) Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res 65:366–373CrossRefPubMed

34.

Tiso N, Stephan DA, Nava A et al (2001) Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 10:189–194CrossRefPubMed

35.

Klauke B, Kossmann S, Gaertner A et al (2010) De novo desmin-mutation N116S is associated with arrhythmogenic right ventricular cardiomyopathy. Hum Mol Genet 19:4595–4607CrossRefPubMed

36.

Taylor M, Graw S, Sinagra G et al (2011) Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes. Circulation 124:876–885CrossRefPubMedCentralPubMed

37.

Corrado D, Basso C, Rizzoli G et al (2003) Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 42:1959–1963CrossRefPubMed

38.

Xu T, Yang Z, Vatta M et al (2010) Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 55:587–597CrossRefPubMedCentralPubMed

39.

Marcus FI, McKenna WJ, Sherrill D et al (2010) Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 121:1533–1541CrossRefPubMedCentralPubMed

40.

Jain R, Dalal D, Daly A et al (2009) Electrocardiographic features of arrhythmogenic right ventricular dysplasia. Circulation 120:477–487CrossRefPubMedCentralPubMed

41.

Wichter T, Paul M, Wollmann C et al (2004) Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation 109:1503–1508CrossRefPubMed

42.

Bhonsale A, James CA, Tichnell C et al (2011) Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol 58:1485–1496CrossRefPubMed

43.

Riele AS te, James CA, Sawant AC et al (2014) Abstract 16401: systematic approach to arrhythmogenic right ventricular dysplasia/cardiomyopathy family screening in a large transatlantic cohort. Circulation 130:A16401

44.

James CA, Tichnell C, Murray B et al (2012) General and disease-specific psychosocial adjustment in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy with implantable cardioverter defibrillators: a large cohort study. Circ Cardiovasc Genet 5:18–24CrossRefPubMed

45.

Marcus GM, Glidden DV, Polonsky B et al (2009) Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC registry. J Am Coll Cardiol 54:609–615CrossRefPubMedCentralPubMed

46.

Philips B, Te Riele AS, Sawant A et al (2014) Outcomes and VT recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm (need page numbers)

47.

Tedford RJ, James C, Judge DP et al (2012) Cardiac transplantation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 59:289–290CrossRefPubMedCentralPubMed

48.

Marcus FI, Fontaine G (1995) Arrhythmogenic right ventricular dysplasia/cardiomyopathy: a review. Pacing Clin Electrophysiol 18:1298–1314CrossRefPubMed

49.

Kirchhof P, Fabritz L, Zwiener M et al (2006) Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation 114:1799–1806CrossRefPubMed

50.

Fabritz L, Hoogendijk MG, Scicluna BP et al (2011) Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. J Am Coll Cardiol 57:740–750CrossRefPubMed

51.

James CA, Bhonsale A, Tichnell C et al (2013) Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol 62:1290–1297CrossRefPubMed

52.

Mitchell JH, Haskell W, Snell P et al (2005) Task Force 8: classification of sports. J Am Coll Cardiol 45:1364–1367CrossRefPubMed

53.

Sawant AC, Murray B, Tichnell C et al (2014) Abstract 11215: exercise influences penetrance and outcomes in family members of arrhythmogenic right ventricular dysplasia/cardiomyopathy patients carrying a pathogenic desmosomal mutation. Circulation 130:A11215

54.

Sawant AC, Bhonsale A, Te Riele AS et al (2014) Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc 3(6):e001471CrossRefPubMedCentralPubMed

55.

Vreeker A, Stuijvenberg L van, Hund TJ et al (2014) Assembly of the cardiac intercalated disk during pre- and postnatal development of the human heart. PLoS One 9:e94722CrossRefPubMedCentralPubMed

56.

Wang Q, Lin JL, Chan SY et al (2013) The Xin repeat-containing protein, mXinbeta, initiates the maturation of the intercalated discs during postnatal heart development. Dev Biol 374:264–280CrossRefPubMedCentralPubMed

57.

Saberniak J, Hasselberg NE, Borgquist R et al (2014) Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members. Eur J Heart Fail 1337–1344

58.

Rojas A, Calkins H (2014) Present understanding of the relationship between exercise and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Trends Cardiovasc Med (Epub ahead of print)

59.

Maron BJ, Zipes DP (2005) Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. J Am Coll Cardiol 45:1318–1321CrossRefPubMed

60.

Pelliccia A, Corrado D, Bjørnstad HH et al (2006) Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. Eur J Cardiovasc Prev Rehabil 13:876–885CrossRefPubMed

61.

Maron BJ, Chaitman BR, Ackerman MJ et al (2004) Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 109:2807–2816CrossRefPubMed

62.

Heidbüchel H, Prior DL, La Gerche A (2012) Ventricular arrhythmias associated with long-term endurance sports: what is the evidence? Br J Sports Med 46(Suppl 1):i44–i50CrossRefPubMed

63.

La Gerche A, Heidbuchel H, Burns AT et al (2011) Disproportionate exercise load and remodeling of the athlete’s right ventricle. Med Sci Sports Exerc 43:974–981CrossRef

64.

Aaron CP, Tandri H, Barr RG et al (2011) Physical activity and right ventricular structure and function. The MESA-Right Ventricle Study. Am J Respir Crit Care Med 183:396–404CrossRefPubMedCentralPubMed

65.

Breuckmann F, Mohlenkamp S, Nassenstein K et al (2009) Myocardial late gadolinium enhancement: prevalence, pattern, and prognostic relevance in marathon runners. Radiology 251:50–57CrossRefPubMed

66.

Benito B, Gay-Jordi G, Serrano-Mollar A et al (2011) Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation 123:13–22CrossRefPubMed

67.

Heidbüchel H (2003) High prevalence of right ventricular involvementin endurance athletes with ventricular arrhythmias role of an electrophysiologic study in risk stratification. Eur Heart J 24:1473–1480CrossRefPubMed

68.

La Gerche A, Robberecht C, Kuiperi C et al (2010) Lower than expected desmosomal gene mutation prevalence in endurance athletes with complex ventricular arrhythmias of right ventricular origin. Heart 96:1268–1274CrossRef

Titel: Sports in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy and desmosomal mutations
verfasst von: A.C. Sawant
H. Calkins, MD
Publikationsdatum: 01.05.2015
Verlag: Urban & Vogel
Erschienen in: Herz / Ausgabe 3/2015
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-015-4223-5

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

24.04.2024 ACC 2024 Nachrichten

Eine FFR-gesteuerte komplette Revaskularisation war in einer Studie bei Patienten mit akutem Myokardinfarkt und koronarer Mehrgefäßerkrankung klinisch nicht wirksamer als eine alleinige Revaskularisation der Infarktarterie.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Coronary artery perforation after crush technique for stent compression

Resolution of cardiac tamponade after chest compression

Screening of athletes

Mitochondrial tRNA glutamine variant in hypertrophic cardiomyopathy